Diagnostic Performance of Serum Biomarkers Fibroblast Growth Factor 21, Galectin-3 and Copeptin for Heart Failure with Preserved Ejection Fraction in a Sample of Patients with Type 2 Diabetes Mellitus

More than half of the patients with heart failure have preserved ejection fraction (HFpEF), however evidence shows a mortality rate comparable to those with reduced ejection fraction. The aim of this study was to evaluate whether FGF21, galectin-3 and copeptin can be used as biomarkers to identify H...

Full description

Bibliographic Details
Published in:	Diagnostics
Main Authors:	Raluca D. Ianoș, Călin Pop, Mihaela Iancu, Rodica Rahaian, Angela Cozma, Lucia M. Procopciuc
Format:	Article
Language:	English
Published:	MDPI AG 2021-08-01
Subjects:	biomarkers heart failure preserved ejection fraction type 2 diabetes mellitus
Online Access:	https://www.mdpi.com/2075-4418/11/9/1577

Similar Items

Predictive Value of NT-proBNP, FGF21, Galectin-3 and Copeptin in Advanced Heart Failure in Patients with Preserved and Mildly Reduced Ejection Fraction and Type 2 Diabetes Mellitus
by: Raluca Diana Ianos, et al.
Published: (2024-11-01)

Heart failure with preserved ejection fraction – onset
by: Branimir Kanazirev
Published: (2021-07-01)

Left Ventricular Strain in Heart Failure with Preserved Ejection Fraction
by: Madhu Shukla, et al.
Published: (2023-01-01)

Predictors and Outcomes of Heart Failure With Preserved Ejection Fraction in Patients With a Left Ventricular Ejection Fraction Above or Below 60%
by: Akito Nakagawa, et al.
Published: (2022-08-01)

Heart failure with preserved ejection fraction: insights from recent clinical researches
by: Mi-Na Kim, et al.
Published: (2020-05-01)

Features of phenotyping patients with heart failure with preserved ejection fraction
by: E. K. Serezhina, et al.
Published: (2023-09-01)

Fibroblast Growth Factor 23 and Risk of New Onset Heart Failure With Preserved or Reduced Ejection Fraction: The PREVEND Study
by: S. Heleen Binnenmars, et al.
Published: (2022-08-01)

Nutrient Intake and Exercise Capacity in Heart Failure With Preserved Ejection Fraction
by: Scott L. Hummel, MD, MS, et al.
Published: (2017-10-01)

Biomarkers in the Pathogenesis of Heart Failure with Preserved as Well as Reduced Ejection Fraction: A Cross-sectional Study
by: Sowmiya Thiyagarajan, et al.
Published: (2025-06-01)

Heart Failure With Preserved Ejection Fraction and Obesity
by: Arjun Sinha, MD, et al.
Published: (2020-01-01)

Comparable effect of tolvaptan in heart failure patients with preserved or reduced ejection fraction
by: Shunsuke Kiuchi, et al.
Published: (2020-02-01)

Invasive haemodynamic assessment in heart failure with preserved ejection fraction
by: Phuuwadith Wattanachayakul, et al.
Published: (2025-06-01)

Prediction model of rehospitalization and mortality in heart failure patients with preserved and mildly reduced ejection fraction: the AD2NNER risk score
by: Flavia-Mihaela Stoiculescu, et al.
Published: (2025-07-01)

Hyperlactataemia is a marker of reduced exercise capacity in heart failure with preserved ejection fraction
by: Emilia Nan Tie, et al.
Published: (2024-10-01)

Impact of plasma xanthine oxidoreductase activity in patients with heart failure with preserved ejection fraction
by: Ken Watanabe, et al.
Published: (2020-08-01)

Markers of heart failure with preserved ejection fraction in patients with unexplained dyspnea
by: A. A. Ivanova, et al.
Published: (2023-11-01)

Impact of intravenous ferric carboxymaltose on heart failure with preserved and reduced ejection fraction
by: Raquel López‐Vilella, et al.
Published: (2022-02-01)

Recurrent heart failure hospitalizations in heart failure with preserved ejection fraction: an analysis of TOPCAT trial
by: Qi Wang, et al.
Published: (2024-02-01)

Heart Failure with Preserved Ejection Fraction in Egypt: An Expert Opinion
by: Magdy Abdelhamid, et al.
Published: (2025-03-01)

Particularities of rhythm and conduction disorders in heart failure patients with preserved ejection fraction admitted to a rehabilitation hospital
by: Marius-Dragoș Mihăilă, et al.
Published: (2024-06-01)

Correlation of β-adrenergic reactivity of erythrocyte membranes with clinical characteristics of patients with coronary artery disease and HF with preserved and reduced ejection fraction
by: E. F. Muslimova, et al.
Published: (2025-01-01)

Clinical and prognostic value of determining the level of neopterin in patients with chronic heart failure with preserved ejection fraction
by: O. S. Polunina, et al.
Published: (2018-10-01)

Heart failure with preserved ejection fraction – new elements of evidence in the field of pathophysiology and new treatment options
by: Branimir Kanazirev
Published: (2021-07-01)

Implications of trial eligibility in patients with heart failure with mildly reduced or preserved ejection fraction
by: Anthony E. Peters, et al.
Published: (2024-10-01)

Cilostazol in patients with heart failure and preserved ejection fraction—The CLIP‐HFpEF trial
by: Norman Aiad, et al.
Published: (2025-04-01)

Importance of non‐cardiovascular comorbidities in atrial fibrillation and heart failure with preserved ejection fraction
by: Yasuhiro Hamatani, et al.
Published: (2025-02-01)

Clinical Usefulness of Speckle-Tracking Echocardiography in Patients with Heart Failure with Preserved Ejection Fraction
by: Yixia Lin, et al.
Published: (2023-09-01)

Heart failure with preserved left ventricular ejection fraction – clinical perspectives
by: Małgorzata Niemiec, et al.
Published: (2025-07-01)

Diagnosis and treatment of heart failure with preserved ejection fraction in patients on hemodialysis
by: Kosaku Nitta, et al.
Published: (2024-10-01)

Catestatin as a predictor for cardiac death in heart failure with mildly reduced and preserved ejection fraction
by: Song‐Yun Chu, et al.
Published: (2025-02-01)

Molecular biomarker profile of heart failure with mid-range and preserved ejection fraction in patients with type 2 diabetes
by: D. A. Lebedev, et al.
Published: (2020-11-01)

Immuno‐haemostatic dysregulation in heart failure with preserved ejection fraction
by: Giorgia D'Italia, et al.
Published: (2025-10-01)

Urinary Proteomics and Outcomes in Heart Failure With Preserved Ejection Fraction
by: Corinne Carland, et al.
Published: (2024-05-01)

Evaluation of renal sodium handling in heart failure with preserved ejection fraction: A pilot study
by: Adhish Agarwal, et al.
Published: (2024-05-01)

CHRONIC HEART FAILURE WITH PRESERVED EJECTION FRACTION: TREATMENT IN CONDITIONS OF LIMITED EVIDENCE
by: S. G. KANORSKIĬ, et al.
Published: (2018-10-01)

Exercise Stress Echocardiography in the Diagnostic Evaluation of Heart Failure with Preserved Ejection Fraction
by: Tomonari Harada, et al.
Published: (2022-03-01)

Heart failure with preserved ejection fraction phenogroup classification using machine learning
by: Atsushi Kyodo, et al.
Published: (2023-06-01)

Temporal prevalence and prognostic impact of diabetes mellitus and albuminuria in heart failure with preserved ejection fraction
by: Nousjka P. A. Vranken, et al.
Published: (2025-04-01)

Cell Therapy for Heart Failure With Preserved Ejection Fraction∗
by: Barry A. Borlaug, MD, et al.
Published: (2016-01-01)

Obesity and metabolic syndrome in patients with heart failure with preserved ejection fraction: a cross-sectional analysis of the Veradigm Cardiology Registry
by: Jay P Bae, et al.
Published: (2024-05-01)